Key result
Bortezomib linked to acute, partially reversible cardiotoxicity with an LVEF drop to 15%.
Why the study?
Proteasome inhibitors like bortezomib are not commonly associated with cardiotoxicity in patients without pre-existing cardiac dysfunction or other cardiotoxic agents, creating uncertainty about their cardiac risks.
Case Report (n=1)
Bortezomib therapy may cause acute, partially reversible left ventricular dysfunction, highlighting the importance of baseline and serial cardiac monitoring in patients receiving proteasome inhibitors.
Answers are grounded in this paper and cite their sources.
Bortezomib may cause acute LV dysfunction in ESRD without prior heart disease; leaves open need for prospective monitoring studies.
Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.
No takes yet. Share an insight, caveat, or question.
Meseeha et al. (2015) conducted a case report in IgG kappa myeloma (n=1). Bortezomib was evaluated on Development of acute left ventricular dysfunction. A 66-year-old woman with end-stage renal disease developed acute, partially reversible left ventricular dysfunction with an ejection fraction drop from 55% to 15% after her third dose of bortezomib.
Synapse has enriched 10 related papers. Consider them for comparative context: